| abstract |
The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc. n n n n n n n n n n n n The symbols in the formula represent the following meanings: n Ar: optionally substituted aryl orn optionally substituted heteroaryl here, the cyclic portion of the heteroaryl is bicyclic heterocyclic ring in which 5- to 6-membered monocyclic heterocyclic ring containing 1 or 2 hetero atom(s) and benzene ring are fused; n n R 1 : a group selected from the group consisting ofn optionally substituted cyclic hydrocarbon group, and optionally substituted heterocyclic group; n n n: an integer of 1 to 3; n X: single bonding arm, —CH 2 —, —CO—, —(CH 2 ) m —CO—, —CH(R 2 )—CO—, —(CH 2 ) p —Y—(C(R 3 )(R 4 )) q —CO—, —NH—CO— or —N(R 5 )—CO—; n in the above-mentioned respective definitions of the X, the bonding arm described at the left end represents a bond with R 1 ; n m is an integer of 1 to 3; n p is an integer of 0 to 2; n q is an integer of 0 to 2; n Y: —O— or —SO 2 —; n R 2 : phenyl or lower alkyl; n R 3 , R 4 : each independently represents hydrogen atom or lower alkyl; n R 5 : lower alkyl; n provided that the ring portion of the group represented by R 1 is neither naphthylidine nor partially saturated group thereof, and, when X is —CH 2 — or —CO—, R 1 is not naphthyl. |